|
|
| (13 intermediate revisions by 4 users not shown) |
| Line 1: |
Line 1: |
| == Market == | | == Summary == |
| === Total addressable market size: ===
| |
| Research shows that approximately 95% of the world has health issues or problems [https://www.sciencedaily.com/releases/2015/06/150608081753.htm#:~:text=Over%2095%25%20of%20the%20world's,than%20five%20ailments%20%2D%2D%20ScienceDaily]. Currently, the world population is at 7.8 billion people. This means that 95% of 7.8 billion people is 7 billion, 410 and million is the addressable market size [https://www.sciencedaily.com/releases/2015/06/150608081753.htm#:~:text=Over%2095%25%20of%20the%20world's,than%20five%20ailments%20%2D%2D%20ScienceDaily].
| |
|
| |
|
| According to Statista, the global pharmaceutical industry had an annual revenue of $1.42 trillion in 2021 [https://pharmanewsintel.com/features/comparing-global-pharmaceutical-markets-the-us-uk-and-china#:~:text=According%20to%20Statista%2C%20the%20global,and%20the%20COVID%2D19%20pandemic.].
| | Summary section of the report needs updating. |
|
| |
|
| In terms of market share, Pfizer held 5% of the world's prescription drug market in 2019 [https://www.statista.com/statistics/309425/prescription-drugs-market-shares-by-top-companies-globally/#:~:text=Pfizer%20held%20five%20percent%20of,the%20global%20market%20until%202026.].
| | [[User:Manos|Manos]] ([[User talk:Manos|talk]]) 08:32, 17 July 2023 (BST) |
|
| |
|
| === Serviceable addressable market size: === | | == References == |
| Here, the total addressable market size is the patient population that was treated with Pfizer vaccines and medicines. This is estimated to be about 1.3 billion patients around the world [https://www.pfizer.com/sites/default/files/investors/financial_reports/annual_reports/2022/files/Pfizer_Annual_Review.pdf]
| |
|
| |
|
| In 2022, the industry is expected to generate 1.14 trillion U.S. dollars in prescription drug revenue worldwide ([https://www.statista.com/statistics/309387/global-total-prescription-drug-revenue-projection/#:~:text=In%202022%2C%20the%20industry%20is,the%20treatment%20of%20rare%20diseases.].
| | Need to add references throughout the report. |
|
| |
|
| === Serviceable Obtainable Market: ===
| | [[User:Manos|Manos]] ([[User talk:Manos|talk]]) 08:32, 17 July 2023 (BST) |
|
| |
|
| The healthcare industry is worth $808 billion in the United States as of 2021 [https://www.crossrivertherapy.com/healthcare-industry-statistics#:~:text=The%20healthcare%20industry%20is%20worth,revenue%20comes%20from%20patient%20care.].
| | == Financial forecasts projects == |
| == Competition == | |
| Despite Pfizer being the leading companies in the biotechnology and pharmaceutical industry, several other large, global drug manufacturers are in competition with Pfizer. These companies include Johnson and Johnson, Roche Holding AG, Novo Nordisk, Merck and Co, AbbVie Inc, and Eli Lilly and Co.
| |
|
| |
|
| In FY 2022, Pfizer made $31.37 billion in net income out of $100.33 billion in annual revenue. The company's market capitalization was $227 billion as of market close on March 24, 2023 [https://s28.q4cdn.com/781576035/files/doc_financials/2022/ar/PFE-2022-Form-10K-FINAL-%28without-Exhibits%29.pdf]. Market cap is used to determine a company's size and then evaluate the company's financial performance to other companies of various sizes. In investing, companies with larger market capitalizations are often safer investments as they represent more established companies with generally longer history in business carrying less risk than small-cap companies.
| | Add the assumptions behind the projections, or if the projections are from a third-party, such as Goldman Sachs, add the source. On reflection, I think the financial forecast assumptions are found in the valuation section of the report? If so, make that clearer in the financial forecasts section of the report. |
|
| |
|
| # Johnson and Johnson:
| | [[User:Manos|Manos]] ([[User talk:Manos|talk]]) 08:32, 17 July 2023 (BST) |
| | |
| * Market cap: $423 billion
| |
| * FY 2022 Revenue: $95 billion
| |
| * FY 2022 Net income: $17.9 billion
| |
| * Top drug by revenue (FY 2022): Darzalex
| |
| * Revenue from top drug (FY 2022): $7.9 billion [https://www.investor.jnj.com/asm/2022-annual-report]
| |
| | |
| Johnson and Johnson is known for its health products, pharmaceuticals and medical devices.
| |
| | |
| 2. Novo Nordisk A/S (NVO):
| |
| | |
| * Market cap: $349 billion [https://www.investopedia.com/markets/quote?tvwidgetsymbol=NVO]
| |
| * FY 2022 Revenue: $43.5 billion
| |
| * FY 2022 Net income: $16.9 billion
| |
| * Top drug by revenue (FY 2022): Ozempic
| |
| * Revenue from top drug (FY 2022): $5.7 billion [https://www.novonordisk.com/investors/financial-results.html#results2023]
| |
| | |
| Novo Nordisk is a Norweigan pharmaceutical company that focuses on treating diabetes, obesity and other serious chronic diseases and conditions. Ozempic was Novo Nordisk's top selling drug in 2022 which is an insulin therapy delivered by injection.
| |
| | |
| 3. Eli Lilly and Co:
| |
| | |
| * Market cap: $440 billion [https://www.investopedia.com/markets/quote?tvwidgetsymbol=LLY]
| |
| * FY 2022 Revenue: $28.5 billion
| |
| * FY 2022 Net income: $6.2 billion
| |
| * Top drug by revenue (FY 2022): Trulicity
| |
| * Revenue from top drug (FY 2022): $5.7 billion [https://investor.lilly.com/static-files/2f9b7bb1-f955-448d-baa2-c4343d39ee62]
| |
| | |
| Eli Lilly is a global drug manufacturing company which focuses on discovering, developing, manufacturing and marketing human pharmaceutical products. The company's top selling drug in FY 2022 was Trulicity which is used to treat type 2 diabetes.
| |
| | |
| 4. Abbvie Inc.
| |
| | |
| * Market Cap: $242 billion [https://www.investopedia.com/markets/quote?tvwidgetsymbol=ABBV]
| |
| * FY 2022 Revenue: $58.1 billion
| |
| * FY 2022 Net Income: $11.8 billion
| |
| * Top Drug by Revenue (FY 2022): Humira
| |
| * Revenue from Top Drug (FY 2022): $18.6 billion ([https://investors.abbvie.com/static-files/e3047152-75b3-44b3-95a8-18e4fa991768]
| |
| | |
| AbbVie is a global biopharmaceutical company engaged in research and development, manufacturing, commercializing and selling innovation medicines and therapies. Its medical products span a range of healthcare-related areas such as immuology, oncology, neuroscience, etc.
| |
| | |
| 5. Merck and Co. Inc
| |
| | |
| * Market Cap: $289 billion
| |
| * FY 2022 Revenue: $59.3 billion
| |
| * FY 2022 Net Income: $16.4 billion
| |
| * Top Drug by Revenue (FY 2022): Keytruda
| |
| * Revenue from Top Drug (FY 2022): $20.9 billion [https://s21.q4cdn.com/488056881/files/doc_financials/2022/ar/b390be48-92bf-4595-96da-ac5cd7c3d92e-%281%29.pdf]
| |
| | |
| The company offers prescription medicines, vaccines, biologic therapies, and animal health products. Its two operating segments are pharmaceutical and animal health.
| |
| | |
| Overall, Pfizer's largest competitor is Johnson and Johnson. Johnson and Johnson may not generate the same amount of revenue from its products but its market cap and total revenue make it a strong competitor.
| |
| | |
| That being said, Pfizer is different from other companies because Pfizer continually emphasises innovation and its multi-billion dollar investment in R and D results in a strong and differentiated product pipeline. The organizational effectiveness of the company is constantly improving by continuously educating patients, physicians, payers and global health authorities on the benefits and risks of medicines and vaccines. Pfizer continues to evaluate, adapt and improve the organisation and business practice in order to meet customer and public needs. Pfizer establishes a "first-to-market" for biosimilar products to provide customers a lower-cost alternative immediately when available as well as providing the company with higher sales and profitability until other competititors enter the market. Pfizer's intellectual property and continuous medicine development are its competitive advantages over other companies [https://www.investopedia.com/ask/answers/052015/who-are-pfizers-pfe-main-competitors.asp].
| |
|
| |
|
| == Research report example == | | == Research report example == |
| Line 79: |
Line 22: |
| == Key source(s) of information == | | == Key source(s) of information == |
| A prime source of insightful information about this company is the company itself. Specifically, the annual report provides comprehensive details about its financial status and business progress. You can access this valuable resource at the following link: [https://investors.pfizer.com/Investors/Overview/default.aspx Pfizer's Annual Report]. Another key source is that of the company's competitors. | | A prime source of insightful information about this company is the company itself. Specifically, the annual report provides comprehensive details about its financial status and business progress. You can access this valuable resource at the following link: [https://investors.pfizer.com/Investors/Overview/default.aspx Pfizer's Annual Report]. Another key source is that of the company's competitors. |
|
| |
| == Risks ==
| |
|
| |
| Following risks or uncertainties include the following:
| |
Summary section of the report needs updating.
Manos (talk) 08:32, 17 July 2023 (BST)Reply[reply]
Need to add references throughout the report.
Manos (talk) 08:32, 17 July 2023 (BST)Reply[reply]
Add the assumptions behind the projections, or if the projections are from a third-party, such as Goldman Sachs, add the source. On reflection, I think the financial forecast assumptions are found in the valuation section of the report? If so, make that clearer in the financial forecasts section of the report.
Manos (talk) 08:32, 17 July 2023 (BST)Reply[reply]
Take a look at this commended research report on Tesla, Inc. from the Stockhub platform: https://stockhub.co/research/Tesla,_Inc. While it has garnered positive feedback, remember that it's simply a reference - there's no obligation to adhere strictly to its style or content.
A prime source of insightful information about this company is the company itself. Specifically, the annual report provides comprehensive details about its financial status and business progress. You can access this valuable resource at the following link: Pfizer's Annual Report. Another key source is that of the company's competitors.
